Company
Headquarters: Taichung, Taiwan
Employees: 94
TW$14.56 Billion
TWD as of Jan. 1, 2024
US$474.4 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Ever Supreme Bio Technology Co., Ltd engages in the research and development of cell gene therapies based on immune cells and stem cells. Its products in development include UMSC01, a drug candidate in Phase 2 clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase 3 clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product in Phase 1 clinical trials for use in the treatment of triple-negative breast cancer; and gene modified mesenchymal stem cells and fucoidan nanoparticles for use in the treatment of malignant tumor. The company was founded in 2016 and is based in Taichung, Taiwan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Ever Supreme Bio Technology Co. Ltd has the following listings and related stock indices.
Stock: TWSE: 6712 wb_incandescent